The Phase Ib open-label single-arm clinical trial will enroll up to approximately 30 patients with relapsed or refractory multiple myeloma at multiple cancer centers in the United States and Europe. Patients will receive escalating doses of SGN-40 in combination with a standard dose of Velcade. The study will assess safety and tolerability of the combination, pharmacokinetics and preliminary activity.
This is the sixth ongoing clinical trial to evaluate SGN-40 either as a single agent or in combination with standard therapies for non-Hodgkin lymphoma and multiple myeloma.
Thomas Reynolds, chief medical officer of Seattle Genetics, said: “This trial is designed to evaluate the safety, tolerability and preliminary activity of the combination of SGN-40 and Velcade, towards the goal of identifying a therapeutic regimen that addresses the significant unmet medical need for these patients.”